NTT Com Launches Renewed SkyWay SDK for More Versatile Development of Online Communication Services
31.1.2023 13:01:00 EET | Business Wire | Press release
NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT group, announced today the immediate launch of the renewed SkyWay software development kit (SDK). The new SkyWay SDK makes it easier than ever to implement real-time voice, video and data communication for applications and websites.
People interested planning or developing online communication services may apply to attend a free webinar in person (50 people) or online (100 people) to learn about the renewed SkyWay SDK at NTT Communications' Tokyo headquarters from 3:00pm (JST) on February 23.
Simple to use and supported with extensive documentation, SkyWay does not require special technical skills or knowledge of voice/video communication or constructing servers, and can be used for a wide range of applications, such as online lessons, IoT and robots. To date, SkyWay has been deployed for the development of more than 20,000 services.
SkyWay is suitable for diverse call formats including voice and video, one-to-one and group calls, and video communication while sharing screens. It also is a multiplatform SDK for developing communication services suited to specific industries and business categories. SkyWay assures high-quality real-time communication, as evidenced by its service uptime rate of 99.96% in fiscal 2021. It also achieves high-quality overseas calls by setting up servers to relay communications to/from Asia, North America and Europe.1 What's more, SkyWay may be used at no charge for service verification and development until the users service is actually launched. Furthermore, fees are adjusted to the scale of service and billing is implemented on a pay-as-you-go billing basis.
Due to the COVID-19 pandemic, online communication has rapidly diversified and now commonly includes events involving dozens of people as well as communication robots. In response, NTT Com decided to upgrade SkyWay's architecture and release it as a new service with enhanced functions for increased versatility, including:
- More simultaneous callers (expanded from 20 to 100 max.)
- Terminal load reduction according to end-user environment (simulcasting2 and API for flexible media transmission/reception, such as only specific video/audio)
- Authentication and authorization for controlling transmission of video/audio to each end user
The following are two examples of SkyWay's expanded functionality.
1. Virtual office
SkyWay can be used to create a system for an office-wide presentation reaching up to 100 people, with simulcasting allowing people to receive audio/video suitably adjusted to each user, such as low-resolution video to reduce system and battery load for mobile devices or terminals with low processing power. Also, participation can be controlled for private conferences.
2. Remote work support
SkyWay also can be used to create a system that allows a supervisor to remotely instruct multiple people at a worksite, using video for detailed directions and only audio if simple verbal directions are sufficient. Selective use of video and/or audio enables the system to reach many people with minimum load.
Service applications will be accepted from January 31. For details, please visit the website or contact a NTT Com sales representative, and for service rates, please see here. (Partially in Japanese only)
Looking ahead, NTT Com expects to further upgrade SkyWay by expanding the scale of voice and video calls, enhancing data communications for synchronization of more people, and supporting gaming platforms for live streaming and the metaverse. In addition, voice and video call experiences will be improved. Also, new SkyWay functions for measuring quality and analyzing problems will increasingly upgrade video and voice in diverse environments. Going forward, NTT Com will continue to develop SkyWay-related business to support the further evolution of real-time communication and its easy implementation by nonexperts in a world where people communicate meaningfully through the power of digital technology.
For more information about SkyWay, please visit here.
1 Technology that enables a terminal to select the most appropriate relay device in order to minimize delay between terminals (granted patent No. 6254620).
2 Technology for transmitting the same video to different terminals using different bitrates, such as low-resolution to mobile devices with limited processing power and bandwidth and high-resolution to PCs.
About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, and more than 500,000m2 of the world's most advanced data-center facilities. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230130005787/en/
Contact information
For more information
SkyWay Promotion Office
Platform Service Division
NTT Communications Corporation
E-mail: skyway@ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
